Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue ...

Ladenburg Growth& Income Fund earns an Average Process Pillar rating. The leading factor in the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the ...

Ladenburg lowered the firm’s price target on Ardelyx (ARDX) to $11 from $13.50 and keeps a Buy rating on the shares following a transfer of ...

Ladenburg Growth Fund earns an Average Process Pillar rating. The main driver of the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the available data ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Fintel reports that on February 26, 2025, Ladenburg Thalmann upgraded their outlook for Spire (NYSE:SR) from Sell to Buy.

ContractHeidelberg Pharma Amends Royalty Financing with HealthCare Royalty 13-March-2025 / 00:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, ...

LADENBURG THALM/SH SH reissued their buy rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The brokerage currently has ...

ChromaDex (NASDAQ:CDXC – Free Report) had its target price upped by LADENBURG THALM/SH SH from $6.80 to $8.10 in a research ...

Detailed price information for Intelligent Bio Solutions Inc (INBS-Q) from The Globe and Mail including charting and trades.

Fintel reports that on February 26, 2025, Ladenburg Thalmann upgraded their outlook for Spire (NYSE:SR) from Sell to Buy. As of February 19, 2025, the average one-year price target for Spire is $ ...